Does reduced amyloid-beta clearance promote amyloid accumulation, tau pathology, and neuronal injury?

The proposed cascade is biologically coherent and substantially supported, but its strongest human evidence concerns amyloid’s downstream relationship with tau rather than direct proof that each clearance pathway fails in vivo.

Amyloid clearance and accumulation

• Blood–brain barrier export has the most direct mechanistic support: in mice, LRP1-mediated transport carried injected Aβ40 across the BBB, while LRP1 blockade prevented recovery of intact Aβ in plasma.
• Impaired perivascular drainage, glymphatic flow, and microglial lysosomal degradation are credible contributors to reduced Aβ removal. Lower DTI-ALPS, an indirect MRI proxy of perivascular/glymphatic function, is associated with greater amyloid-PET burden, but does not directly measure Aβ drainage.
• Human stable-isotope kinetic studies found slower Aβ40 and Aβ42 clearance in Alzheimer disease without a significant production-rate difference. This is consistent with impaired clearance allowing accumulation when production continues.

Tau pathology and neuronal injury

• Longitudinal PET evidence strongly supports amyloid as a promoter of later tau accumulation. In cognitively unimpaired individuals, baseline amyloid predicted faster tau accumulation and was the sole independent predictor in one analysis (P < .001).
• Experimental evidence is concordant: intracerebral Aβ42 increased neurofibrillary-tangle burden about fivefold in P301L tau-transgenic mice, indicating that amyloid can amplify tau vulnerability rather than independently generate the complete tau process.
• Soluble Aβ oligomers can disrupt synaptic plasticity, glutamatergic signaling, and excitatory–inhibitory balance; inflammatory glial responses may further contribute. In human cohorts, amyloid burden relates to neuroaxonal-injury markers, while tau PET is more strongly associated with plasma neurofilament light after cognitive impairment develops.

Bottom line

• The overall claim is well grounded: reduced Aβ clearance is a credible route to amyloid accumulation, and amyloid accumulation promotes tau pathology and neuronal injury. BBB transport is experimentally supported; the perivascular, glymphatic, and cellular pathways remain biologically persuasive but are less directly validated in living humans.